ClinicalTrials.gg
CompletedNCT06021951Updated Apr 11, 2025Results posted

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

A Phase 4 interventional study of Bempedoic Acid 180 MG Oral Tablet and Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet in Healthy Lactating Women, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Esperion Therapeutics, Inc. · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study is designed to characterize the excretion of bempedoic acid or bempedoic acid and ezetimibe into mature breast milk of healthy lactating women and assess the exposure to the breast fed infant by estimating the daily infant dosage and the relative infant dose (RID) of bempedoic acid or bempedoic acid and ezetimibe in breast milk after 6 consecutive daily doses of bempedoic acid or bempedoic acid/ezetimibe FCDP.

Read the detailed description

Post marketing approval commitment for the FDA

02

Conditions studied

  • Healthy Lactating Women

Keywords

  • Bempedoic acid
  • Ezetimibe
  • Bempedoic acid and ezetimibe
  • Breast Milk
03

In context

Lead sponsor

Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must be a lactating female who had a normal full-term pregnancy and has been actively breastfeeding or pumping for at least 4 weeks; lactation must be well established per Investigator discretion.
  • The subject must be willing to pump regularly during the study to maintain milk supply and discontinue breastfeeding for the entire 13-day Treatment and .
  • The subject must not be pregnant.
  • The subject must be surgically sterile or willing to use 1 acceptable method of .

Exclusion criteria

Exclusion Criteria:

  • Has infection (e.g., pneumonia, pyelonephritis) or chronic infection within 30 days prior to enrollment.
  • Has evidence of unstable or uncontrolled, clinically significant cardiovascular, central nervous system, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder, including serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash, that, in the opinion of the Investigator, would confound the study results or compromise subject safety.
  • Has estimated (eGFR) \<30 mL/min/1.732 using the Modification of Diet in Renal Disease (MDRD) formula.
  • Has liver disease or dysfunction characterized by Class B or Class C.
  • History of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  • Has active psychiatric problems that, in the Investigator's opinion, may interfere with compliance with the study procedures.
  • Has history of breast implants, breast augmentation, or breast reduction surgery.
  • Has a prior history of difficulty establishing lactation.
  • Gastrointestinal conditions or procedures (including weight loss surgery; e.g., Lap-Band® or gastric bypass) that may affect drug absorption.
  • Any history of (with the exception only of basal or squamous cell carcinoma of the skin in individuals that have been cancer free for >5 years).
  • History within the last 2 years of drug, alcohol, amphetamine and derivatives, or cocaine abuse.
  • Current smoker.
  • Blood donation, participation in a multiple blood draw clinical study, major trauma, or surgery with or without blood loss within 30 days prior to enrollment.
  • Blood transfusion for any reason within 90 days prior to enrollment.
  • Use of any 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor (statin) concurrently or within 30 days prior to randomization.
  • Use of cyclosporine, cholestyramine, probenecid, fibrate drugs, or medications during lactation concurrently or within 30 days prior to randomization.
  • Concomitant use or use within 30 days prior to randomization of drugs that decrease breast milk production, such as pseudoephedrine.
  • Concomitant use or use within 30 days prior to randomization of drugs that increase breast milk production, such as domperidone.
  • Use of any experimental or drugs/vaccines concurrently or within 30 days or 5 half-lives of the drug, whichever is longer, prior to screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Bempedoic acid

    Drug: Bempedoic Acid 180 MG Oral Tablet

  • Experimental
    Bempedoic acid/ezetimibe fixed combination drug product

    Drug: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet

Interventions

  • Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]

    Also known as: Nexletol

  • DrugBempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet

    Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]

    Also known as: Nexlizet 180 mg-10 mg

06

What researchers measure

Primary outcomes

  1. Daily Infant Dose

    Daily infant dosage of study drug was calculated for Bempedoic Acid arm and FCDP arm respectively from the cumulative amount of study drug (bempedoic acid or bempedoic acid and ezetimibe) excreted in breast milk over 24 hours.

    Time frame: 24 hours post Day 6 dose administration

  2. Relative Infant Dose (RID)

    Relevant Infant Dose (RID) (calculated as the ratio of estimated infant daily dose per kg body weight and maternal daily dose per kg of body weight multiplied by 100) was analyzed for the Bempedoic Acid arm and FCDP arm respectively. Maternal dosage is the ratio of bempedoic acid dose or ezetimibe dose administered daily divided by maternal body weight at baseline.

    Time frame: 24 hours post Day 6 dose administration

Secondary outcomes

  1. Cumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk

    Cumulative amount of ETC-1002, ESP-15228, and ETC-1002-glucuronide excreted in breast milk during the 24-hour collection period were analyzed for the Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  2. Cumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk

    Cumulative amount of Ezetimibe, and EZE-glucuronide excreted in breast milk during 24-hour collection period were analyzed (FCDP arm only).

    Time frame: 24 hours post Day 6 dose administration

  3. Maximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk

    Cmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively

    Time frame: 24 hours post Day 6 dose administration

  4. Cmax of Ezetimibe and Metabolite in Breast Milk

    Cmax of Ezetimibe, and EZE-glucuronide analyzed in FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  5. Time of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk

    Tmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively

    Time frame: 24 hours post Day 6 dose administration

  6. Tmax of Ezetimibe and Metabolite in Breast Milk

    Tmax of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  7. Area Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk

    AUC24h of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  8. AUC24h of Ezetimibe and Metabolite in Breast Milk

    AUC24h of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  9. Average Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk

    Cavg (defined as AUC24h/24h) of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  10. Cavg of Ezetimibe and Metabolite in Breast Milk

    Cavg of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  11. Trough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk

    Ctrough_milk of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  12. Ctrough of Ezetimibe and Metabolite in Breast Milk

    Ctrough_milk of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  13. Ctrough of Bempedoic Acid and Metabolites in Plasma

    Ctrough_plasma of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  14. Ctrough of Ezetimibe and Metabolite in Plasma

    Ctrough_plasma of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

  15. Ctrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites

    M/P Ratio of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

    Time frame: 24 hours post Day 6 dose administration

  16. M/P Ratio of Ezetimibe and Metabolite

    M/P Ratio of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

    Time frame: 24 hours post Day 6 dose administration

07

Results

Posted Apr 11, 2025

Participant flow

This was a Phase 4, open-label study that estimated the daily infant dosage and relative infant dose (RID) for bempedoic acid and bempedoic acid/ezetimibe fixed combination drug product (FCDP) and characterized the excretion of bempedoic acid (ETC-1002), ezetimibe, and metabolites ESP-15228, ETC-1002-glucuronide, and ezetimibe-glucuronide in the mature breast milk of healthy women.

Participant flow — Overall Study
MilestoneBempedoic AcidBempedoic Acid/Ezetimibe FCDP
Started88
Completed88
Not completed00

Outcome measures

PrimaryDaily Infant Dose

Daily infant dosage of study drug was calculated for Bempedoic Acid arm and FCDP arm respectively from the cumulative amount of study drug (bempedoic acid or bempedoic acid and ezetimibe) excreted in breast milk over 24 hours.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Mean · Milligrams per day
Daily Infant Dose
Milligrams per dayBempedoic AcidBempedoic Acid (FCDP)Ezetimibe (FCDP)
Daily Infant Dose0.0331 ± 0.02100.0337 ± 0.02860.0002 ± 0.0002
PrimaryRelative Infant Dose (RID)

Relevant Infant Dose (RID) (calculated as the ratio of estimated infant daily dose per kg body weight and maternal daily dose per kg of body weight multiplied by 100) was analyzed for the Bempedoic Acid arm and FCDP arm respectively. Maternal dosage is the ratio of bempedoic acid dose or ezetimibe dose administered daily divided by maternal body weight at baseline.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Mean · Percentage of maternal dose
Relative Infant Dose (RID)
Percentage of maternal doseBempedoic AcidBempedoic Acid (FCDP)Ezetimibe (FCDP)
Relative Infant Dose (RID)0.4790 ± 0.19620.4678 ± 0.28890.0370 ± 0.0097
SecondaryCumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk

Cumulative amount of ETC-1002, ESP-15228, and ETC-1002-glucuronide excreted in breast milk during the 24-hour collection period were analyzed for the Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Mean · Nanograms
Cumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk
NanogramsETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Cumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk33120.0 ± 21034.1114207.4 ± NA20690.5 ± 6554.4833673.4 ± 28635.66770.0 ± NA20709.1 ± 16012.78
SecondaryCumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk

Cumulative amount of Ezetimibe, and EZE-glucuronide excreted in breast milk during 24-hour collection period were analyzed (FCDP arm only).

Time frame:
24 hours post Day 6 dose administration
Reported as:
Mean · Nanograms
Cumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk
NanogramsEzetimibeEZE-Glucuronide
Cumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk182.2 ± 154.97983.0 ± 996.16
SecondaryMaximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk

Cmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk
Nanograms per milliliterETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Maximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk118.15 ± 38.91NA ± NA73.06 ± 56.59107.46 ± 43.19NA ± NA57.29 ± 56.35
SecondaryCmax of Ezetimibe and Metabolite in Breast Milk

Cmax of Ezetimibe, and EZE-glucuronide analyzed in FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Cmax of Ezetimibe and Metabolite in Breast Milk
Nanograms per milliliterEzetimibeEZE-Glucuronide
Cmax of Ezetimibe and Metabolite in Breast Milk0.63 ± 44.292.93 ± 54.02
SecondaryTime of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk

Tmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively

Time frame:
24 hours post Day 6 dose administration
Reported as:
Median · Hours
Time of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk
HoursETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Time of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk2.94 (2.8 to 6.0)NA (NA to NA)8.92 (5.7 to 12.0)2.93 (2.8 to 8.9)NA (NA to NA)8.93 (5.8 to 19.7)
SecondaryTmax of Ezetimibe and Metabolite in Breast Milk

Tmax of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Median · Hours
Tmax of Ezetimibe and Metabolite in Breast Milk
HoursEzetimibeEZE-Glucuronide
Tmax of Ezetimibe and Metabolite in Breast Milk2.93 (2.8 to 6.0)5.88 (2.8 to 8.9)
SecondaryArea Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk

AUC24h of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Hours*nanograms per milliliter
Area Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk
Hours*nanograms per milliliterETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Area Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk1765.86 ± 40.88NA ± NA1308.84 ± 56.241618.25 ± 39.67NA ± NA1057.69 ± 43.21
SecondaryAUC24h of Ezetimibe and Metabolite in Breast Milk

AUC24h of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric least squares mean · Hours*nanograms per milliliter
AUC24h of Ezetimibe and Metabolite in Breast Milk
Hours*nanograms per milliliterEzetimibeEZE-Glucuronide
AUC24h of Ezetimibe and Metabolite in Breast Milk7.79 ± 38.2941.09 ± 66.10
SecondaryAverage Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk

Cavg (defined as AUC24h/24h) of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Average Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk
Nanograms per milliliterETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Average Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk74.181 ± 40.75NA ± NA54.982 ± 55.9867.848 ± 39.77NA ± NA44.346 ± 43.42
SecondaryCavg of Ezetimibe and Metabolite in Breast Milk

Cavg of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric least squares mean · Nanograms per milliliter
Cavg of Ezetimibe and Metabolite in Breast Milk
Nanograms per milliliterEzetimibeEZE-Glucuronide
Cavg of Ezetimibe and Metabolite in Breast Milk0.327 ± 38.411.723 ± 66.03
SecondaryTrough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk

Ctrough_milk of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Trough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk
Nanograms per milliliterETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Trough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk50.58 ± 47.59NA ± NA45.55 ± 62.7258.60 ± 53.36NA ± NA39.32 ± 51.81
SecondaryCtrough of Ezetimibe and Metabolite in Breast Milk

Ctrough_milk of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of Ezetimibe and Metabolite in Breast Milk
Nanograms per milliliterEzetimibeEZE-Glucuronide
Ctrough of Ezetimibe and Metabolite in Breast Milk0.25 ± 38.661.33 ± 82.37
SecondaryCtrough of Bempedoic Acid and Metabolites in Plasma

Ctrough_plasma of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of Bempedoic Acid and Metabolites in Plasma
Nanograms per milliliterETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Ctrough of Bempedoic Acid and Metabolites in Plasma10025.6 ± 25.461862.4 ± 34.044904.9 ± 35.659665.9 ± 37.951641.8 ± 20.784984.7 ± 35.65
SecondaryCtrough of Ezetimibe and Metabolite in Plasma

Ctrough_plasma of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of Ezetimibe and Metabolite in Plasma
Nanograms per milliliterEzetimibeEZE-Glucuronide
Ctrough of Ezetimibe and Metabolite in Plasma2.29 ± 69.3735.76 ± 77.54
SecondaryCtrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites

M/P Ratio of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Ratio
Ctrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites
RatioETC-1002ESP-15228ETC-1002-GlucuronideETC-1002 (FCDP)ESP-15228 (FCDP)ETC-1002-Glucuronide (FCDP)
Ctrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites0.005 ± 25.35NA ± NA0.009 ± 29.050.006 ± 59.39NA ± NA0.008 ± 63.91
SecondaryM/P Ratio of Ezetimibe and Metabolite

M/P Ratio of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.

Time frame:
24 hours post Day 6 dose administration
Reported as:
Geometric mean · Ratio
M/P Ratio of Ezetimibe and Metabolite
RatioEzetimibeEZE-Glucuronide
M/P Ratio of Ezetimibe and Metabolite0.108 ± 62.210.037 ± 81.68

Adverse events

Collected over Up to Day 43. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bempedoic Acid0/8 (0%)0/8 (0%)4/8 (50%)
Bempedoic Acid / Ezetimibe FCDP0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventBempedoic AcidBempedoic Acid / Ezetimibe FCDP
DiarrhoeaGastrointestinal disorders0/82/8
VomitingGastrointestinal disorders0/82/8
AstheniaGeneral disorders0/82/8
HeadacheNervous system disorders2/80/8
Abdominal discomfortGastrointestinal disorders1/81/8
Abdominal pain upperGastrointestinal disorders0/81/8
NauseaGastrointestinal disorders0/81/8
RhinitisInfections and infestations1/80/8
Alanine aminotransferase increasedInvestigations0/81/8
Aspartate aminotransferase increasedInvestigations0/81/8

Baseline characteristics

Full Analysis Set comprised of all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Bempedoic AcidBempedoic Acid/Ezetimibe FCDPTotal
Mean33.5 ± 4.1727.1 ± 4.0930.3 ± 5.17
Sex: Female, Male
Sex: Female, Male(Participants)Bempedoic AcidBempedoic Acid/Ezetimibe FCDPTotal
Female8816
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bempedoic AcidBempedoic Acid/Ezetimibe FCDPTotal
Hispanic or Latino033
Not Hispanic or Latino8513
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bempedoic AcidBempedoic Acid/Ezetimibe FCDPTotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander011
Black or African American134
White437
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • PPD Development, Las Vegas Research Unit
    Las Vegas, Nevada 89113, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Feb 2024, 6 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2023
First posted
Sep 1, 2023
StartActual
Aug 4, 2023
Primary completionActual
Feb 21, 2024
CompletionActual
Mar 22, 2024
Results first posted
Apr 11, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06021951
Responsible party
Sponsor
First posted
Sep 1, 2023
Start date
Aug 4, 2023
Primary completion
Feb 21, 2024
Completion
Mar 22, 2024
Results posted
Apr 11, 2025
Last update
Apr 11, 2025

Study contacts

Christine Broestl, MS
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion